#$SLDB
LightNews LightNews
notreload.bsky.social
#$ABTC #$EAT #$CMG #$FTH #$FIVN #$TRAX #$SHAK #$SBUX #$SLDB #$SLVM #$TXRH #$ZNTL #$EXPE #$TARS -- THE WSJ
September 16, 2026 at 1:50 PM
lundimatin.bsky.social
"Nous pourrissons en régime bourgeois et policier"

En guise d'hommage à Catherine Ringer, ces deux extraits introuvables de son opéra-rock Flashes rouges de 1979 que nous avions exhumés il y a quelques années.

www.youtube.com/watch?v=slDB...
Flashes rouges (extrait 1)
YouTube video by lundimatin
www.youtube.com
September 15, 2026 at 9:03 PM
paperposterbot.bsky.social
arXiv📈🤖
Sliced $L^p$ Distributional Balancing
By Zhang, Chen, Park
A popular class of causal inference methods addresses confounding through weighting, which reweights treated and control groups to balance their covariate distributions without using outcome information, thereby preserving a design-based perspective. In this paper, we propose sliced $L^p$ distributional balancing (SLDB), a family indexed by $p\in[1,\infty)$ that measures imbalance by averaging squared $L^p$ distances between the cumulative distribution functions of one-dimensional linear projections. The Cram\'er--Wold device ensures that this criterion identifies equality of multivariate distributions, while projection reduces its computation to sorting-based one-dimensional operations. Because our method lies outside the maximum mean discrepancy (MMD) framework underlying many existing distributional balancing methods, their theoretical and computational tools do not directly apply. We therefore develop a computationally efficient projected subgradient descent algorithm for estimating balancing weights, offering improved computational complexity over MMD-based methods. Furthermore, we establish a novel theoretical framework for SLDB-based causal effect estimation and prove, under suitable conditions, $\sqrt{n}$-consistency and asymptotic normality, with the asymptotic variance attaining the semiparametric efficiency bound. Finally, we develop inferential procedures that do not require augmentation with an outcome model, thereby retaining the design-based principle. Simulation studies and a real-world application demonstrate that SLDB performs competitively with existing methods.
September 10, 2026 at 6:09 AM
saintluciagov.bsky.social
The Government of St. Lucia guaranteed a US$20 million (EC$54 million) financing facility between the St. Lucia Development Bank (SLDB) and Taiwan Eximbank at a Tuesday signing at SLDB headquarters.

Read more: www.govt.lc/news/st-luci...
August 27, 2026 at 7:15 PM
notreload.bsky.social
Truist restarts #$SLDB at Buy/$20 (≈120% upside). JPMorgan backs #$STOK at Overweight/$40. Cash into 2028. notreload.xyz/xy/truist-jp...
Truist & JPMorgan Restart Coverage on SLDB & STOK
Truist restarts Solid Biosciences at Buy/$20. JPMorgan backs Stoke Therapeutics at Overweight/$40. Cash into 2028.
notreload.xyz
August 21, 2026 at 4:21 PM
tickzen.bsky.social
Price target forecast update for SLDB (SLDB). Horizon: 12 months. Average target: $0.6310 (-93.1% move). #SLDB
TickZen Stock scorecard chart
August 18, 2026 at 9:46 AM
quant-hub.bsky.social
🚨 $SLDB
On August 6, 2026, Solid Biosciences Inc. filed a prospectus supplement under the Company’s universal shelf registration statement on Form S-3 (File No. 333-287325) that was originally filed with the Securities and Exchange Commission on May 15, 2025 and was declared effective by the SEC ...
SEC Filing: SLDB
Click to view the official SEC document.
www.sec.gov
August 6, 2026 at 9:36 PM
stocktitan.net
#SLDB Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

https://www.stocktitan.net/news/SLDB/solid-biosciences-reports-second-quarter-2026-financial-results-and-oc6b20ig32i3.html
Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
Solid Biosciences (Nasdaq: SLDB) reported second quarter 2026 results and clinical updates. Cash, cash equivalents and available-for-sale securities were $377.7 million as of June 30, 2026, up from $187.9 million at year-end 2025, with a cash runway expected to extend into mid-2028, according to the company.SGT-003 for Duchenne has been generally well tolerated in 53 participants in the Phase 1/2 INSPIRE DUCHENNE trial, and dosing has begun in the Phase 3 IMPACT DUCHENNE trial. Solid plans an FDA meeting in late Q4 2026 to seek guidance on a potential accelerated approval pathway. SGT-212 for Friedreich’s ataxia has shown no treatment-related serious adverse events in two dosed participants, with initial data expected in Q1 2027. SGT-501 for CPVT is in Phase 1b site-activation and screening, with first dosing targeted for 2H 2026. The company has executed 50+ agreements for its POLARIS-101™ capsid.Q2 2026 R&D expenses were $44.3 million and G&A expenses $13.1 million, leading to a net loss of $54.8 million, compared with a $39.5 million net loss in Q2 2025.
www.stocktitan.net
August 6, 2026 at 8:09 PM
feuer.social.feuerx.net.ap.brid.gy
Onko javalle olemassa slime-debuggerin (sldb) kaltaista työkalua emacsiin tai komentoriville?
August 4, 2026 at 12:37 PM
snakemanvt.northsky.social
Hell yeah it is starlight.kirara.ca/card/301239
Card: SSR Yumemi Riamu (sldb)
starlight.kirara.ca
August 2, 2026 at 5:14 PM
quant-hub.bsky.social
🚨 $SLDB
RA CAPITAL MANAGEMENT, L.P. () initiated ownership with 12,036,126 shares (plus 1 other holdings) upon appointment.
SEC Filing: SLDB
Click to view the official SEC document.
www.sec.gov
June 24, 2026 at 10:51 PM
quant-hub.bsky.social
🚨 $SLDB
Nagendran Sukumar (Insider) reported special transactions (Non-P/S).
SEC Filing: SLDB
Click to view the official SEC document.
www.sec.gov
June 11, 2026 at 8:20 PM
quant-hub.bsky.social
🚨 $SLDB
Ganot Ilan (Insider) reported special transactions (Non-P/S).
SEC Filing: SLDB
Click to view the official SEC document.
www.sec.gov
June 11, 2026 at 8:20 PM
quant-hub.bsky.social
🚨 $SLDB
PERCEPTIVE ADVISORS LLC (Insider) reported special transactions (Non-P/S).
SEC Filing: SLDB
Click to view the official SEC document.
www.sec.gov
June 11, 2026 at 8:19 PM
quant-hub.bsky.social
🚨 $SLDB
Keresty Georgia (Insider) reported special transactions (Non-P/S).
SEC Filing: SLDB
Click to view the official SEC document.
www.sec.gov
June 11, 2026 at 8:19 PM
quant-hub.bsky.social
🚨 $SLDB
Freed Martin I (Insider) reported special transactions (Non-P/S).
SEC Filing: SLDB
Click to view the official SEC document.
www.sec.gov
June 11, 2026 at 8:19 PM
quant-hub.bsky.social
🚨 $SLDB
Kahn Clare (Insider) reported special transactions (Non-P/S).
SEC Filing: SLDB
Click to view the official SEC document.
www.sec.gov
June 11, 2026 at 8:17 PM
quant-hub.bsky.social
🚨 $SLDB
Stone Adam Leo (Insider) reported special transactions (Non-P/S).
SEC Filing: SLDB
Click to view the official SEC document.
www.sec.gov
June 11, 2026 at 8:15 PM
quant-hub.bsky.social
🚨 $SLDB
Solid Biosciences Inc. held its Annual Meeting of Stockholders on June 10, 2026 to consider and vote upon the matters listed below.
SEC Filing: SLDB
Click to view the official SEC document.
www.sec.gov
June 10, 2026 at 8:13 PM
ettodesune.bsky.social
月星のRマン316 いわゆるロケットの洗脳というやつじゃあ...
www.youtube.com/watch?v=Sldb...
月星のRマン316 いわゆるロケットの洗脳というやつじゃあ...
YouTube video by kaishoki
www.youtube.com
June 4, 2026 at 12:45 PM
slobberjabber.bsky.social
Buy $SLDB (SLDB.O) @ 11:03:19
June 3, 2026 at 10:03 AM
stocktitan.net
#SLDB Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

https://www.stocktitan.net/news/SLDB/solid-biosciences-doses-first-participant-in-phase-3-impact-duchenne-6pqpdv4tpq0a.html
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
Solid Biosciences (Nasdaq: SLDB) dosed the first participant in its multi-country, randomized, placebo-controlled Phase 3 IMPACT DUCHENNE trial of SGT-003 on May 7, 2026. The program complements the Phase 1/2 INSPIRE trial where 46 participants have received SGT-003 and it has been generally well tolerated as of a May 4, 2026 cutoff.The company received a positive EMA PIP opinion for pediatric development, holds FDA Fast Track, Rare Pediatric and Orphan Drug designations, and was awarded a UK Innovation Passport under ILAP.
www.stocktitan.net
May 7, 2026 at 12:00 PM
stocktitan.net
#SLDB Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

https://www.stocktitan.net/news/SLDB/solid-biosciences-to-showcase-a-large-presence-at-the-29th-annual-frsfr87lthiv.html
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
Solid Biosciences (Nasdaq: SLDB) will present its largest scientific program at the 29th ASGCT Annual Meeting in Boston, May 11–15, 2026. The company will deliver 16 presentations (5 oral, 11 posters) covering clinical updates, next-generation delivery, capsid engineering and scalable AAV manufacturing.
www.stocktitan.net
April 30, 2026 at 12:00 PM
stocktitan.net
#SLDB Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

https://www.stocktitan.net/news/SLDB/solid-biosciences-announces-receipt-of-european-commission-orphan-6v8f0412vxk0.html
EU grants orphan status to Solid’s Duchenne gene therapy candidate
The designation adds to U.S. Fast Track and Rare Pediatric Disease status. Solid is testing SGT-003 in Phase 1/2 and Phase 3 Duchenne trials.
www.stocktitan.net
April 28, 2026 at 12:00 PM
clark208.bsky.social
BEFORE THE BREAK UPDATE (STOCKS) UPDATE: PLAY-by-PLAYTRADING SYSTEM:
TICKER-SLDB
GREEN CANDLE CLOSE OVER 8.10= CONTINUATION
8.30- QUICK SCALP
8.50+ IF MOMENTUM STACKS
April 6, 2026 at 5:12 PM